



NAVIGATING RISK: GENETIC COUNSELING & HIGH-RISK SCREENING

Brittany Adams, MMSc, CGC
Licensed, Certified Genetic Counselor
Winship Cancer Institute at Emory Johns Creek Hospital

Breast Cancer Awareness Month Symposium, 2025
October 11, 2025

EMORY
WINSHIP
CANCER
INSTITUTE
DESIGNATED COMPREHENSIVE
CANCER CENTER

NCI
Designated
Comprehensive
Cancer Center

1

CONFLICTS OF INTEREST

None

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center

2

LEARNING OBJECTIVES

Define the role of genetic counseling in the evaluation and management of patients at risk for hereditary cancer syndromes

Identify appropriate candidates for genetic testing based on personal and family history criteria


Describe recommended high-risk screening strategies and how they integrate into patient care following genetic test results

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center

3

THE ROLE OF A GENETIC COUNSELOR



Genetic counselors

- Master's degree in genetic counseling
- Certified by the American Board of Genetic Counseling (ABGC) or the American Board of Medical Genetics (ABMG)

Other healthcare providers with specialized training in genetics

- MD geneticists
- Genetic nurse clinicians
- Other genetic sub-specialists

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center

4

WHAT HAPPENS DURING A GENETIC COUNSELING VISIT

An initial genetic counseling visit includes:

- Review of personal and family medical histories
- Assessment of risk for hereditary cancer
- Discussion of cancer biology and genetics
- Discussion of genetic testing options and/or referrals for additional evaluation if appropriate
- Discussion of implications of testing for the patient and their family
- Review insurance concerns




The initial genetic counseling typically lasts 1 to 1½ hours

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 5

5

DNA, GENES, AND GENETIC TESTING




WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 6

6

DNA, GENES, AND GENETIC TESTING




- A type of medical test that identifies changes in chromosomes, genes, or proteins.
- The results of a genetic test:
 - can confirm or rule out a suspected genetic condition
 - or help determine a person's chance of developing or passing on a genetic disorder

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 7

7

AUTOSOMAL DOMINANT INHERITANCE




WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 8

8

ALL CANCER IS GENETIC, BUT NOT ALL CANCER IS HEREDITARY




WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 9

9


WHEN IS CANCER HEREDITARY?



WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 10

10




SPORADIC CANCER

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 11

11




FAMILIAL CANCER

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 12

12



13

RISK FACTORS FOR HEREDITARY BREAST CANCER

- Early onset cancer diagnosis**
 - Diagnosed at age 50 or younger
- Multiple cancer primaries in the same individual**
 - Bilateral breast cancer, breast and ovarian cancer
- Same or related types of cancer in 2+ close on the same side of the family**
 - Parent, sibling, child, aunt/uncle
 - Breast/ovarian/pancreatic/prostate cancer can be "related"
- Multiple generations of cancer within a family**
 - Grandparents, children, and their grandchildren with cancer
- Rare types of cancer**
 - Male breast cancer, ovarian cancer, pancreatic cancer
- Ashkenazi Jewish ancestry**
- Anyone who has a close family member who meets the above criteria**

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY NCI Designated Comprehensive Cancer Center 14

14

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)


Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

Testing is clinically indicated in the following scenarios:

- See General Testing Criteria on CRIT-1.
- Personal history of breast cancer with specific features:
 - 50 y
 - Any age:
 - Treatment indications
 - To aid in systemic treatment decisions using PARP inhibitors for breast cancer in the metastatic setting^{4,5} (See [NCCN Guidelines for Breast Cancer](#))
 - To aid in adjuvant treatment decisions with olaparib for high-risk,⁶ HER2-negative breast cancer⁷
 - Pathology/histology
 - Triple-negative breast cancer
 - Multiple primary breast cancers (synchronous or metachronous)⁸
 - Lobular breast cancer with personal or family history of diffuse gastric cancer (See [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric](#))
 - Male breast cancer
 - Ancestry: Ashkenazi Jewish
 - Any age (continued):
 - Family history⁹
 - ≥1 close blood relative⁹ with ANY:
 - breast cancer at age 50 y
 - male breast cancer
 - ovarian cancer
 - pancreatic cancer
 - prostate cancer with metastatic⁹ or high- or very-high-risk group (Initial Risk Stratification and Staging Workup in [NCCN Guidelines for Prostate Cancer](#))
 - ≥3 diagnoses of breast and/or prostate cancer (any grade) on the same side of the family including the patient with breast cancer
- Family history criteria: unaffected; or affected but does not meet above criteria
- Individual with a first- or second-degree blood relative meeting any of the criteria listed above (except unaffected individuals whose relatives meet criteria only for systemic therapy decision-making).⁷
- Individuals who have a probability >5% of a *BRCA1/2* P/LP variant based on prior probability models (eg, Tyrer-Cuzick, BRCAPro, CanRisk).³


WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY NCI Designated Comprehensive Cancer Center 15

15



16

DOES THIS FAMILY MEET GENETIC TESTING CRITERIA?



WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 17

17

Breast/Ovarian cancer risk genes

High-risk genes
4-5 fold cancer risk

GENE (S)	ASSOCIATED CANCERS
<i>BRCA1 / BRCA2</i>	Breast, ovarian, pancreas, prostate, fallopian
<i>TP53</i>	Breast, sarcoma, brain, adrenocortical, and more
<i>PTEN</i>	Breast, thyroid, uterine, and non-cancer findings
<i>CDH1</i>	Breast and stomach
<i>STK11</i>	Breast, colon, stomach, specific polyps, and more
<i>ATM</i>	Breast, ovarian, prostate and pancreatic
<i>CHEK2</i>	Breast, prostate, thyroid, and uterine
<i>PALB2</i>	Breast, ovarian, and pancreatic
<i>BARD1</i>	Breast and ovarian
<i>BRIP1</i>	Breast and ovarian
<i>FANCC</i>	Breast
<i>NBN</i>	Breast and ovarian
<i>RAD51C, RAD51D</i>	Breast and ovarian

Moderate-risk genes
2-3 fold cancer risk

Newer genes
1-2 fold cancer risk

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 18

18

HIGH RISK SCREENING VS MODERATE RISK SCREENING

BRCA1/2

Lifetime risk of breast cancer: >60%

Age 18: Breast awareness

Age 25: Clinical breast exam, every 6-12 months

Age 25-29: Annual breast MRI

Age 30-75: Annual mammogram and breast MRI

Optional:

- Bilateral mastectomy- reduce risk of breast cancer by ≥90%

ATM

Lifetime risk of breast cancer: 20-40%

Age 30-35: Consider annual breast MRI

Age 40-75: Annual mammogram and breast MRI

*begin at age 40 or 10 years before the earliest breast cancer diagnosis

Risk reducing mastectomy not recommended

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 19

19

HIGH RISK, BUT NEGATIVE GENETIC TESTING RESULT

Patient has a lifetime risk ≥20% as defined by models that include a comprehensive family history

Models are used to help assess someone's risk for breast cancer or a *BRCA* mutation

Model Examples:

- BRCAPRO, Tyrer Cuzick, BOADICEA/CanRisk, Breast Cancer Surveillance Consortium (BCSC) Invasive Breast Cancer Risk Calculator

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 20

20

TYRER CUZICK/IBIS MODEL

More comprehensive for breast cancer risk

Uses personal information and family history information to provide a lifetime risk of breast cancer:

- Age
- Height and weight
- Breast density
- Age at first menstrual period
- Age at birth of first child
- Age at menopause
- Personal history of hormone use
- Family history of breast and ovarian cancer

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 21

21

HIGH RISK BREAST CANCER SCREENING: ≥20% LIFETIME RISK

To begin when patient is identified as high risk:


- Initiate annual mammographic screening at age 40, or 10 years prior to the earliest breast cancer diagnosis in a relative—whichever comes first—but not before age 30
- Initiate annual breast MRI screening at age 40, or 10 years prior to the earliest breast cancer diagnosis in a relative—whichever comes first—but not before age 25.
- Consider risk reduction strategies
- Breast awareness

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 22

22

GENETIC COUNSELING CARE PATHWAY



WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 23

23

WINSHIP GENETIC COUNSELING PROGRAM

Genetic Counselors

- Christine Stanislaw, MS, CGC – Clifton
- Suzy Cahn, MMSc, CGC – Clifton, Decatur
- Claire Kelso, MS, CGC – Clifton
- Fabienne Ehivet, MS, CGC – St. Joseph's
- Rachel Cohn-Lynch, MS, CGC – Midtown
- Tatiana Garrison Johnson, MMSc, CGC – Midtown
- Brittany Adams, MMSc, CGC – Johns Creek

Appointments

- 404.778.1900
- Internal referral in EPIC: Add order – select Genetics – Cancer Genetics
- Telemedicine and in-person available

Website

- <https://winshipcancer.emory.edu/genetic-counseling.html>

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY

NCI Designated Comprehensive Cancer Center 24

24

SOURCES

National Comprehensive Cancer Network. (2025). *Breast cancer screening and diagnosis (Version 1.2025)*. NCCN Clinical Practice Guidelines in Oncology. <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1410>

National Comprehensive Cancer Network. (2025). *Genetic/familial high-risk assessment: Breast, ovarian, pancreatic, and prostate (Version 1.2026)*. NCCN Clinical Practice Guidelines in Oncology. <https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1545>

Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. *Stat Med*. 2004;23(7):1111–1130. doi:10.1002/sim.1668

IBIS Breast Cancer Risk Evaluation Tool. Available at: <https://www.ems-trials.org/riskevaluator/>

Thank you!
Do you have any questions?

Brittany.a.adams@emoryhealthcare.org